GlycoMimetics, a clinical-stage biotech developing treatments for sickle cell episodes and AML, postponed its IPO on Friday. The Gaithersburg, MD-based company was founded in 2003 and booked $12 million in sales for the 12 months ended June 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
